Ocuphire Pharma (OCUP)
(Delayed Data from NSDQ)
$1.72 USD
-0.24 (-12.24%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.70 -0.02 (-1.16%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.72 USD
-0.24 (-12.24%)
Updated May 10, 2024 04:00 PM ET
After-Market: $1.70 -0.02 (-1.16%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Zacks News
All You Need to Know About Ocuphire Pharma, Inc. (OCUP) Rating Upgrade to Buy
by Zacks Equity Research
Ocuphire Pharma, Inc. (OCUP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ocuphire Pharma, Inc. (OCUP) Loses 17.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Ocuphire Pharma, Inc. (OCUP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.